Merck Earnings Preview: Can This Streak Continue?
Merck & Co. (NYSE:MRK) will report earnings before markets open on Wednesday, May 1st. Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
Here is your Cheat Sheet to Merck & Co. Earnings:
Earnings Expectations: Analysts expect earnings of $0.78 per share on revenues of $11.10 billion. Currently, the company’s P/E ratio stands at 23.98.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.93 to a profit $0.92. For the current year, the average estimate is a profit of $3.63, which is worse than the estimate ninety days ago.
Here’s how Merck & Co. has been performing on an annual basis:
|Revenue ($) in millions||23,850||27,430||45,990||48,050||47,270|
|Diluted EPS ($)||3.63||5.65||0.28||2.02||2.00|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||12,290||11,730||12,310||11,490||11,740|
|Diluted EPS ($)||0.4925||0.56||0.58||0.56||0.2952|
Merck & Co. has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)